Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: In vitro examination of the thrombolytic efficacy of tenecteplase and therapeutic ultrasound compared to rt-PA

Fig. 2

Results from dose finding experiments with tenecteplase (TNK): Weight loss measurements after 1 and 2 h of treatment with escalating dosages from 0 to 40 μg/ml TNK (n = 10 for every dosage) were performed to determine the maximum effective dosage for TNK. Bars reflect the standard deviation (SD) from the mean. For reasons of clarity, we omitted the SD of the control group (SD for 1 h: 5.7%; SD for 2 h: 7.4%)

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us